High-Dose Deferoxamine in Intracerebral Hemorrhage
Status:
Terminated
Trial end date:
2018-05-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine whether treatment with deferoxamine mesylate
is of sufficient promise to improve outcome before pursuing a larger clinical trial to
examine its effectiveness as a treatment for brain hemorrhage.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Dalhousie University Duke University Hartford Hospital Henry Ford Hospital Hopital de l'Enfant-Jesus Johns Hopkins University Massachusetts General Hospital Medical University of South Carolina National Institute of Neurological Disorders and Stroke (NINDS) Ohio State University Oregon Health and Science University Rhode Island Hospital St. Joseph's Hospital and Medical Center, Phoenix Stanford University The Cleveland Clinic The University of Texas Health Science Center, Houston Tufts Medical Center University of Alberta University of Calgary University of California, San Francisco University of Florida University of Iowa University of Maryland University of Maryland, College Park University of Massachusetts, Worcester University of North Carolina University of Pennsylvania University of Virginia University of Washington Yale New Haven Hospital